Prime Medicine, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PRME Nasdaq 2836 primemedicine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Prime Medicine, Inc.

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference - Jan 7th, 2026 6:00 am
LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases - Dec 31st, 2025 9:12 am
Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data - Dec 30th, 2025 9:45 pm
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease - Dec 7th, 2025 6:05 am
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference - Nov 25th, 2025 6:00 am
Prime Medicine to Present at Jefferies Global Healthcare Conference - Nov 11th, 2025 6:00 am
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates - Nov 7th, 2025 8:21 am
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates - Nov 7th, 2025 6:10 am
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates - Nov 7th, 2025 5:00 am
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer - Nov 3rd, 2025 6:01 am
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$174m decrease in market cap last week, although long-term gains have benefitted them. - Oct 31st, 2025 4:55 am
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy - Oct 30th, 2025 2:01 pm
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates - Oct 30th, 2025 6:20 am
Prime Medicine to Participate in Upcoming Investor Conferences - Oct 7th, 2025 6:00 am
Prime Medicine (PRME): Evaluating Valuation After Recent LNP Innovations Spotlighted at Cell & Gene Therapy Conference - Sep 20th, 2025 5:56 am
Will Prime Medicine's (PRME) Innovation Messaging at CGTI Drive Lasting Competitive Advantage? - Sep 18th, 2025 5:31 am
Why Cathie Wood is Loading Up on These 2 Growth Stocks (And Should You?) - Sep 15th, 2025 2:50 pm
Positive Signs As Multiple Insiders Buy Prime Medicine Stock - Aug 20th, 2025 4:17 am
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates - Aug 7th, 2025 7:10 am
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates - Aug 7th, 2025 6:00 am